Access Pharmaceuticals (ACCP), a growing biopharmaceutical company with a focus on oncology, has released financial results for the first quarter of this year, which ended on March 31, 2o13. The Dallas-based company’s lead product, MuGard, has been approved for sale in the United States and Europe, as well as South Korea and China.
http://bionews-tx.com/news/2013/05/21/access-pharmaceuticals-of-dallas-reports-first-quarter-2013-results/
No comments:
Post a Comment